111 related articles for article (PubMed ID: 32345708)
1. Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.
Tadrous M; Martins D; Mamdani MM; Gomes T
CMAJ Open; 2020; 8(2):E297-E303. PubMed ID: 32345708
[TBL] [Abstract][Full Text] [Related]
2. Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis.
Tadrous M; Daniels B; Pearson SA; Gomes T
CMAJ Open; 2021; 9(4):E1048-E1054. PubMed ID: 34815260
[TBL] [Abstract][Full Text] [Related]
3. Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs.
Kim SH; Ryu YJ; Cho NE; Kim AE; Chang J
Clin Drug Investig; 2017 Oct; 37(10):957-963. PubMed ID: 28735450
[TBL] [Abstract][Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
6. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
7. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
9. Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Programs.
Lee K; Jani T; Cheng R; Hunt J
Healthc Q; 2020 Apr; 23(1):10-12. PubMed ID: 32249733
[TBL] [Abstract][Full Text] [Related]
10. Estimated cost of universal public coverage of prescription drugs in Canada.
Morgan SG; Law M; Daw JR; Abraham L; Martin D
CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and healthcare utilisation patterns of high-cost beneficiaries in the Netherlands: a cross-sectional claims database study.
Wammes JJG; Tanke M; Jonkers W; Westert GP; Van der Wees P; Jeurissen PP
BMJ Open; 2017 Nov; 7(11):e017775. PubMed ID: 29133323
[TBL] [Abstract][Full Text] [Related]
12. The relationship between type of drug therapy and blood glucose self-monitoring test strips claimed by beneficiaries of the Seniors' Pharmacare Program in Nova Scotia, Canada.
Sanyal C; Graham SD; Cooke C; Sketris I; Frail DM; Flowerdew G
BMC Health Serv Res; 2008 May; 8():111. PubMed ID: 18501012
[TBL] [Abstract][Full Text] [Related]
13. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015-2021: a repeated cross-sectional study.
Gaudette É; Rizzardo S; Zhang Y; Pothier KR; Tadrous M
BMJ Open; 2024 Mar; 14(3):e082568. PubMed ID: 38485176
[TBL] [Abstract][Full Text] [Related]
15. Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs.
Kang SY; Sen A; Bai G; Anderson GF
JAMA; 2019 Aug; 322(5):422-429. PubMed ID: 31386135
[TBL] [Abstract][Full Text] [Related]
16. Identifying drugs with the greatest increases and decreases in spending per beneficiary using Medicare Part D: A cross-sectional study.
Hodzic-Santor B; Sacks CA; Van Bakel T; Fralick M
PLoS One; 2023; 18(2):e0281076. PubMed ID: 36758003
[TBL] [Abstract][Full Text] [Related]
17. Cost-control mechanisms in Canadian private drug plans.
Kratzer J; McGrail K; Strumpf E; Law MR
Healthc Policy; 2013 Aug; 9(1):35-43. PubMed ID: 23968672
[TBL] [Abstract][Full Text] [Related]
18. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
Murry L; Gerleman B; Urick B; Urmie J
J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
[TBL] [Abstract][Full Text] [Related]
19. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14.
Dusetzina SB
Health Aff (Millwood); 2016 Jul; 35(7):1241-6. PubMed ID: 27385240
[TBL] [Abstract][Full Text] [Related]
20. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
Kennedy J; Morgan S
Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
